 |
|
 |
|
 |
|
|
MasterVIEW is a new unrivalled product line which brings together all our new vaccine product evaluations in one place to the country level.
From new vaccines to prevent bacterial infections such as Shigella, hospital-acquired infections, and other types of meningitis, right through to vaccines for chronic disorders, MasterVIEW covers
new product concepts that have accounted for >80% of new vaccine clinical trials since 2014.
MasterVIEW is composed of fixed or semi-customizable Executive presentations (.pdf) and data sheet(s) (.xls). It is designed for clients who want
a detailed comparative landscape view or commercial attractiveness audit of multiple new vaccine product opportunities for strategic planning, M&A and/or formulation of R&D strategy.
Example product features are:
 More than 65 new vaccine product opportunities by pathogen/disease/sub-segment
R&D intensity, most advanced stage/competitor, predicted launch date(s)
Pricing trends, expected schedule, target segments and other key datasets
Revised & adjusted product/sub-segment and total revenue forecasts to 2035
Dynamic and future proof - can respond to changes
Will roll-out across major markets during 2026
MasterVIEW products will soon also be available for existing/mature vaccine markets
| CAT No: |
Market: |
Contents: |
Date: |
| VAMS001 |
 |
Click here |
To order 2021 |
*This is a licensed product. Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.
For information on how to order
e-mail: Info@vacZine-analytics.com
|
|
|
|
|
|
